MIRA Pharmaceuticals, Inc. Increase (Decrease) in Other Receivables
MIRA Pharmaceuticals, Inc. (MIRA) reported Increase (Decrease) in Other Receivables of -$11.86 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherReceivables · last filed 2026-03-31
- MIRA Pharmaceuticals, Inc. increase (decrease) in other receivables for the quarter ending 2024-12-31 was $0.00.
- MIRA Pharmaceuticals, Inc. increase (decrease) in other receivables for the quarter ending 2024-09-30 was $0.00.
- MIRA Pharmaceuticals, Inc. increase (decrease) in other receivables for the quarter ending 2024-06-30 was $0.00.
- MIRA Pharmaceuticals, Inc. increase (decrease) in other receivables for the quarter ending 2024-03-31 was -$11.86K.
- MIRA Pharmaceuticals, Inc. increase (decrease) in other receivables for fiscal 2024 was -$11.86K, a 200.00% decline from fiscal 2023.
- MIRA Pharmaceuticals, Inc. increase (decrease) in other receivables for fiscal 2023 was $11.86K.
| Period end | Increase (Decrease) in Other Receivables 3 month | Increase (Decrease) in Other Receivables 6 month | Increase (Decrease) in Other Receivables 9 month | Increase (Decrease) in Other Receivables 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $0.00 derived: sum of 3 quarters · filed 2026-03-31 | -$11.86K 10-K · filed 2026-03-31 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | -$11.86K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$11.86K 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | -$11.86K 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $11.86K 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |